Vis enkel innførsel

dc.contributor.authorGeiseler, Samuel
dc.contributor.authorMorland, Cecilie
dc.date.accessioned2018-08-03T13:52:04Z
dc.date.accessioned2018-09-25T11:49:59Z
dc.date.available2018-08-03T13:52:04Z
dc.date.available2018-09-25T11:49:59Z
dc.date.issued2018-05-04
dc.identifier.citationGeiseler J, Morland C. The janus face of VEGF in stroke. International Journal of Molecular Sciences. 2018;19:1362(5):1-20en
dc.identifier.issn1422-0067
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/10642/6204
dc.description.abstractThe family of vascular endothelial growth factors (VEGFs) are known for their regulation ofvascularization. Inthebrain,VEGFsareimportantregulatorsofangiogenesis,neuroprotectionand neurogenesis. Dysregulation of VEGFs is involved in a large number of neurodegenerative diseases and acute neurological insults, including stroke. Stroke is the main cause of acquired disabilities, and normally results from an occlusion of a cerebral artery or a hemorrhage, both leading to focal ischemia. Neurons in the ischemic core rapidly undergo necrosis. Cells in the penumbra are exposed to ischemia, but may be rescued if adequate perfusion is restored in time. The neuroprotective and angiogenic effects of VEGFs would theoretically make VEGFs ideal candidates for drug therapy in stroke. However, contradictory to what one might expect, endogenously upregulated levels of VEGF as well as the administration of exogenous VEGF is detrimental in acute stroke. This is probably due to VEGF-mediated blood–brain-barrier breakdown and vascular leakage, leading to edema and increased intracranial pressure as well as neuroinflammation. The key to understanding this Janus face of VEGF function in stroke may lie in the timing; the harmful effect of VEGFs on vessel integrity is transient, as both VEGF preconditioning and increased VEGF after the acute phase has a neuroprotective effect. The present review discusses the multifaceted action of VEGFs in stroke prevention and therapy.en
dc.description.sponsorshipNorges forskningsråd 262647en
dc.language.isoenen
dc.publisherMDPIen
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;Volume 19, Issue 5
dc.rights© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Creative Commons-lisensen er mer spesifikt Attribution 4.0 International (CC BY 4.0).en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectGrowth factorsen
dc.subjectVascular endothelial growth factorsen
dc.subjectStrokesen
dc.subjectIschemiaen
dc.subjectExerciseen
dc.titleThe janus face of VEGF in strokeen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2018-08-03T13:52:04Z
dc.description.versionpublishedVersionen
dc.identifier.doihttp://dx.doi.org/10.3390/ijms19051362
dc.identifier.cristin1589401
dc.source.journalInternational Journal of Molecular Sciences


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Creative Commons-lisensen er mer spesifikt Attribution 4.0 International (CC BY 4.0).
Med mindre annet er angitt, så er denne innførselen lisensiert som © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Creative Commons-lisensen er mer spesifikt Attribution 4.0 International (CC BY 4.0).